Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (NASDAQ: GLUE), a biotechnology company focused on novel molecular glue degrader (MGD)-based medicines, announced that CEO Markus Warmuth is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 11:15 a.m. PT. The presentation will be accessible via the company’s investor site, with an archived version available for 90 days.

Monte Rosa's innovative approach utilizes a proprietary platform called QuEEN™ to identify therapeutic protein targets for drug development.

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 41^st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 11:15 a.m. PT.

The webcast of the presentation will be accessible via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.com/, and an archived version will be made available for 90 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader (MGD) medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and MGD product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection, and computational chemistry capabilities to predict and obtain protein degradation profiles. For more information, visit www.monterosatx.com. 

Investors
Shai Biran, Monte Rosa Therapeutics
ir@monterosatx.com

Media
Dan Budwick, 1AB
dan@1abmedia.com

FAQ

What is the scheduled date and time for the presentation by Monte Rosa Therapeutics at the J.P. Morgan Healthcare Conference?

Markus Warmuth, CEO of Monte Rosa Therapeutics, is scheduled to present on January 11, 2023, at 11:15 a.m. PT.

Where can I access the webcast of Monte Rosa Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

The webcast of the presentation will be available in the 'Events & Presentations' section of Monte Rosa Therapeutics' investor site.

What does Monte Rosa Therapeutics focus on in biotechnology?

Monte Rosa Therapeutics develops novel molecular glue degrader (MGD)-based medicines that selectively eliminate therapeutically relevant proteins.

What is QuEEN™ and how does it relate to Monte Rosa Therapeutics?

QuEEN™ is Monte Rosa Therapeutics' proprietary protein degradation platform designed to rapidly identify protein targets for drug discovery.

How long will the archived version of the Monte Rosa Therapeutics presentation be available?

The archived version of the presentation will be available for 90 days following the live event.